Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
J Natl Compr Canc Netw ; 19(9): 1021-1026, 2021 09 20.
Artigo em Inglês | MEDLINE | ID: mdl-34551389

RESUMO

The cost of delivering high-quality healthcare in America now consumes 17.7% of the nation's gross domestic product according to Centers for Medicare & Medicaid Services National Health Expenditure Data. With costs threatening to disrupt accessible and equitable care for patients, policymakers are reassessing all matters and functions of the healthcare system to excise waste, redundancies, and costly services. To explore this subjects' impact on oncology, NCCN hosted the NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High Quality Cancer Care. This virtual summit featured multidisciplinary panel discussions and keynote addresses. Seeking to address barriers to low-cost, high-quality cancer care, panelists and keynotes presented innovative policy solutions to sustain high-quality oncologic care at lower costs to the health system. This article encapsulates the discussions held during the summit and expounds upon salient points where appropriate.


Assuntos
Medicare , Neoplasias , Idoso , Atenção à Saúde , Política de Saúde , Humanos , Oncologia , Neoplasias/terapia , Qualidade da Assistência à Saúde , Estados Unidos
2.
Surg Endosc ; 29(10): 2984-93, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25552232

RESUMO

BACKGROUND: Patients have a unique role in deciding what treatments should be available for them and regulatory agencies should take their preferences into account when making treatment approval decisions. This is the first study designed to obtain quantitative patient-preference evidence to inform regulatory approval decisions by the Food and Drug Administration Center for Devices and Radiological Health. METHODS: Five-hundred and forty United States adults with body mass index (BMI) ≥ 30 kg/m(2) evaluated tradeoffs among effectiveness, safety, and other attributes of weight-loss devices in a scientific survey. Discrete-choice experiments were used to quantify the importance of safety, effectiveness, and other attributes of weight-loss devices to obese respondents. A tool based on these measures is being used to inform benefit-risk assessments for premarket approval of medical devices. RESULTS: Respondent choices yielded preference scores indicating their relative value for attributes of weight-loss devices in this study. We developed a tool to estimate the minimum weight loss acceptable by a patient to receive a device with a given risk profile and the maximum mortality risk tolerable in exchange for a given weight loss. For example, to accept a device with 0.01 % mortality risk, a risk tolerant patient will require about 10 % total body weight loss lasting 5 years. CONCLUSIONS: Patient preference evidence was used make regulatory decision making more patient-centered. In addition, we captured the heterogeneity of patient preferences allowing market approval of effective devices for risk tolerant patients. CDRH is using the study tool to define minimum clinical effectiveness to evaluate new weight-loss devices. The methods presented can be applied to a wide variety of medical products. This study supports the ongoing development of a guidance document on incorporating patient preferences into medical-device premarket approval decisions.


Assuntos
Cirurgia Bariátrica/instrumentação , Tomada de Decisões , Regulamentação Governamental , Preferência do Paciente , Comportamento de Escolha , Estudos Transversais , Humanos , Obesidade/cirurgia , Medição de Risco , Inquéritos e Questionários , Estados Unidos , United States Food and Drug Administration
3.
Nanomedicine ; 9(5): 594-9, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23692697

RESUMO

Emerging technologies result when advances and innovation in technology lead to discoveries. Often emerging technologies stimulate novel research in medical product development that contribute to new approaches to manufacturing and can improve the quality of products. By supporting investments in agency coordination, staff training and professional development, regulatory science research, stakeholder engagement, and enhancing opportunities for expert input, the U.S. Food and Drug Administration plays a critical role in translating innovations into novel safe and effective medical products that improve the public health.


Assuntos
Investimentos em Saúde/economia , Nanotecnologia/economia , Pesquisa/economia , United States Food and Drug Administration/economia , Humanos , Saúde Pública , Estados Unidos
8.
Sci Transl Med ; 4(163): 163fs43, 2012 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-23209277

RESUMO

The FDA announces a partnership with a new nonprofit organization--the Medical Device Innovation Consortium--to advance regulatory science in the medical technology arena.


Assuntos
Equipamentos e Provisões , Estados Unidos , United States Food and Drug Administration
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA